-transparent.png){kind=logo}
BACKGROUND 111In-radiolabelled (DTPA-D-Phe1)-octreotide scintigraphy can be used to localize neuroendocrine tumours expressing somatostatin receptors (SSTRs). The aim of this paper was to analyse the importance of tumour volume and growth for the visualization by SSTR scintigraphy of metastases from medullary thyroid carcinoma (MTC). METHODS Serum calcitonin concentrations were used to estimate volume and growth rate of MTC. Twenty-two patients who had persistent hypercalcitoninaemia after total thyroidectomy for MTC, indicating the presence of metastases, were studied. RESULTS SSTR scintigraphy visualized 15 tumours in 11 patients. Patients with scintigraphically visualized tumours had higher serum calcitonin and carcinoembryonic antigen concentrations and larger tumours, and the serum calcitonin concentration increased more rapidly with time. Tumour-associated symptoms and death from MTC occurred only in patients with scintigraphically visualized tumours. CONCLUSIONS Scintigraphically visualized tumours grow more rapidly and are more aggressive than nonvisualized lesions. SSTR scintigraphy can be helpful in the planning of palliative surgery for MTC and for diagnosing distant metastases, but cannot localize microscopic metastases.
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
June 1993,
Nuclear medicine communications,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
January 1996,
Digestion,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
October 2007,
European journal of nuclear medicine and molecular imaging,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
May 1994,
Clinical nuclear medicine,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
January 1999,
Nuklearmedizin. Nuclear medicine,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
January 1995,
Clinical endocrinology,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
December 1995,
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
February 1995,
Nuklearmedizin. Nuclear medicine,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
January 1993,
Hormone and metabolic research. Supplement series,
L E Tisell, and
H Ahlman, and
B Wängberg, and
G Hansson, and
J Mölne, and
O Nilsson, and
G Lindstedt, and
M Fjälling, and
E Forssell-Aronsson
July 1998,
The Journal of clinical endocrinology and metabolism,
